ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Johnson & Johnson has confirmed that it will not enforce the patents for its tuberculosis treatment bedaquiline, marketed as Sirturo. The drug’s primary patent expired earlier this year; after a public campaign, J&J granted a Swiss nonprofit licenses to produce generic versions. The announcement is intended to reassure other companies that want to manufacture generic versions, the firm says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter